Slam Corp. (SLAM)
NASDAQ: SLAM
· Real-Time Price · USD
11.14
-0.01 (-0.09%)
At close: Aug 26, 2024, 10:00 PM
-0.09% (1D)
Bid | n/a |
Market Cap | 261.27M |
Revenue (ttm) | n/a |
Net Income (ttm) | 5.85M |
EPS (ttm) | -0.04 |
PE Ratio (ttm) | -278.5 |
Forward PE | n/a |
Analyst | n/a |
Ask | n/a |
Volume | 77,569 |
Avg. Volume (20D) | 85,619 |
Open | 11.14 |
Previous Close | 11.15 |
Day's Range | 11.14 - 11.14 |
52-Week Range | 10.73 - 11.24 |
Beta | 0.01 |
About SLAM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SLAM
Website n/a

2 weeks ago · accessnewswire.com
SLAM IP Survey Expands Target Beneath Farquharson Copper-Nickel-Cobalt Zone At GoodwinHigh-Resolution IP Survey Shows Potential At Depth MIRAMICHI, NB / ACCESS Newswire / August 21, 2025 / SLAM Exploration Ltd. ("SLAM" or the "Company") (TSXV-SXL) is pleased to announce results for Lin...

2 months ago · accessnewswire.com
SLAM Reports Gold Assays From 7.42 to 94.80 g/t Gold and Announces Resignation of Director/CFONew Assay Results from Jake Lee Claims Confirms Recent Discovery MIRAMICHI, NB / ACCESS Newswire / July 9, 2025 / SLAM Exploration Ltd. (TSXV:SXL) ("SLAM" or the "Company") is pleased to report additi...

2 months ago · seekingalpha.com
Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull CaseProtagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...